Grand Pharmaceutical Group Limited (0512.HK)
HKD 5.76
(-2.54%)
HKD 5.76
(-2.54%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 2.66 Billion HKD | 5.79% |
| 2022 | 2.51 Billion HKD | 24.72% |
| 2021 | 2.01 Billion HKD | 33.75% |
| 2020 | 1.5 Billion HKD | 29.42% |
| 2019 | 1.16 Billion HKD | 30.7% |
| 2018 | 892.3 Million HKD | 34.01% |
| 2017 | 665.87 Million HKD | 45.47% |
| 2016 | 457.74 Million HKD | 28.21% |
| 2015 | 357.01 Million HKD | 18.97% |
| 2014 | 300.08 Million HKD | 58.37% |
| 2013 | 189.47 Million HKD | 20.44% |
| 2012 | 157.32 Million HKD | 24.99% |
| 2011 | 125.86 Million HKD | -32.09% |
| 2010 | 185.34 Million HKD | 248.36% |
| 2009 | 53.2 Million HKD | 703.35% |
| 2008 | 6.62 Million HKD | -86.06% |
| 2007 | 47.52 Million HKD | 601.12% |
| 2006 | 6.77 Million HKD | -93.37% |
| 2005 | 102.28 Million HKD | -29.64% |
| 2004 | 145.37 Million HKD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 1.37 Billion HKD | 0.0% |
| 2023 FY | 2.66 Billion HKD | 5.79% |
| 2023 Q2 | 1.53 Billion HKD | 0.0% |
| 2023 Q4 | 1.12 Billion HKD | 0.0% |
| 2022 FY | 2.51 Billion HKD | 24.72% |
| 2022 Q2 | 1.33 Billion HKD | 0.0% |
| 2022 Q4 | 1.25 Billion HKD | 0.0% |
| 2021 Q4 | 921.35 Million HKD | 0.0% |
| 2021 FY | 2.01 Billion HKD | 33.75% |
| 2021 Q2 | 1.04 Billion HKD | 0.0% |
| 2020 Q4 | 707.09 Million HKD | 0.0% |
| 2020 Q2 | 793.37 Million HKD | 0.0% |
| 2020 FY | 1.5 Billion HKD | 29.42% |
| 2019 Q4 | 492.88 Million HKD | 0.0% |
| 2019 FY | 1.16 Billion HKD | 30.7% |
| 2019 Q2 | 680.55 Million HKD | 0.0% |
| 2018 FY | 892.3 Million HKD | 34.01% |
| 2018 Q2 | 515.91 Million HKD | 0.0% |
| 2018 Q4 | 376.38 Million HKD | 0.0% |
| 2017 FY | 665.87 Million HKD | 45.47% |
| 2017 Q2 | 351.94 Million HKD | 0.0% |
| 2017 Q4 | 313.92 Million HKD | 0.0% |
| 2016 Q4 | 235.95 Million HKD | 0.0% |
| 2016 Q2 | 221.78 Million HKD | 0.0% |
| 2016 FY | 457.74 Million HKD | 28.21% |
| 2015 Q4 | 189.47 Million HKD | 0.0% |
| 2015 Q2 | 167.53 Million HKD | 0.0% |
| 2015 FY | 357.01 Million HKD | 18.97% |
| 2014 Q4 | 170.29 Million HKD | 0.0% |
| 2014 Q2 | 129.78 Million HKD | 0.0% |
| 2014 FY | 300.08 Million HKD | 58.37% |
| 2013 Q4 | 112.31 Million HKD | 0.0% |
| 2013 FY | 189.47 Million HKD | 20.44% |
| 2013 Q2 | 77.16 Million HKD | 0.0% |
| 2012 Q2 | 29.98 Million HKD | 0.0% |
| 2012 FY | 157.32 Million HKD | 24.99% |
| 2012 Q4 | 51.07 Million HKD | 70.33% |
| 2012 Q3 | 29.98 Million HKD | 0.0% |
| 2012 Q1 | 29.98 Million HKD | 0.0% |
| 2011 Q2 | 23.35 Million HKD | 0.0% |
| 2011 Q3 | 23.35 Million HKD | 0.0% |
| 2011 Q4 | 29.98 Million HKD | 28.37% |
| 2011 FY | 125.86 Million HKD | -32.09% |
| 2011 Q1 | 23.35 Million HKD | 0.0% |
| 2010 Q1 | 38.45 Million HKD | 0.0% |
| 2010 Q3 | 38.45 Million HKD | 0.0% |
| 2010 Q4 | 23.35 Million HKD | -39.26% |
| 2010 FY | 185.34 Million HKD | 248.36% |
| 2010 Q2 | 38.45 Million HKD | 0.0% |
| 2009 Q1 | 15.51 Million HKD | 0.0% |
| 2009 Q3 | 15.51 Million HKD | 0.0% |
| 2009 Q4 | 38.45 Million HKD | 147.84% |
| 2009 FY | 53.2 Million HKD | 703.35% |
| 2009 Q2 | 15.51 Million HKD | 0.0% |
| 2008 Q2 | -2.04 Million HKD | 0.0% |
| 2008 Q4 | 15.51 Million HKD | 859.38% |
| 2008 Q1 | -2.04 Million HKD | 0.0% |
| 2008 FY | 6.62 Million HKD | -86.06% |
| 2008 Q3 | -2.04 Million HKD | 0.0% |
| 2007 Q1 | -11.25 Million HKD | 0.0% |
| 2007 Q4 | -2.04 Million HKD | 81.84% |
| 2007 Q3 | -11.25 Million HKD | 0.0% |
| 2007 Q2 | -11.25 Million HKD | 0.0% |
| 2007 FY | 47.52 Million HKD | 601.12% |
| 2006 Q4 | -11.25 Million HKD | -269.33% |
| 2006 FY | 6.77 Million HKD | -93.37% |
| 2006 Q2 | -3.04 Million HKD | 0.0% |
| 2006 Q3 | -3.04 Million HKD | 0.0% |
| 2006 Q1 | -3.04 Million HKD | 0.0% |
| 2005 Q2 | -27.2 Million HKD | 0.0% |
| 2005 Q4 | -3.04 Million HKD | 88.8% |
| 2005 FY | 102.28 Million HKD | -29.64% |
| 2005 Q1 | -27.2 Million HKD | 0.0% |
| 2005 Q3 | -27.2 Million HKD | 0.0% |
| 2004 Q2 | -39.12 Million HKD | 0.0% |
| 2004 Q3 | -39.12 Million HKD | 0.0% |
| 2004 Q1 | -39.12 Million HKD | 0.0% |
| 2004 Q4 | -27.2 Million HKD | 30.48% |
| 2004 FY | 145.37 Million HKD | 0.0% |
| 2003 Q4 | -39.12 Million HKD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | -1762.359% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | 32731.671% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | -6415.159% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | 5203.955% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | -7289.704% |
| Essex Bio-Technology Limited | 310.32 Million HKD | -758.247% |
| Tongfang Kontafarma Holdings Limited | - HKD | -Infinity% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 4132.639% |
| SSY Group Limited | 1.63 Billion HKD | -62.511% |
| JBM (Healthcare) Limited | 174.2 Million HKD | -1428.887% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | -699.516% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 78.074% |